MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,FHFIB N	SA00064516	47	F	SA00064516
Ordering Phys CLIENT,CLIENT				**DOB** 06/10/1966
Client Order # SA00064516	**Account Information**			**Report Notes**
Collected 11/18/2013 08:00	C7028846-DLMP Rochester SDSC 2 - Client Support Rochester, MN 55901			
Printed 11/20/2013 08:22				

Test	Flag	Results	Unit	Reference Value	Perform Site*
HCV FibroSURE					
RECEIVED: 11/19/2013 14:52 **REPORTED:** 11/19/2013 15:07					
HCV FibroSURE Results:		Result Below			Y060
Fibrosis Score	H	0.90		0.00 - 0.21	Y060
Fibrosis Stage		F4-Cirrhosis			Y060
Necroinflammat Activity Score	H	0.97		0.00 - 0.17	Y060
Necroinflammat Activity Grade		A3-Severe activity			Y060
Analysis:		Result Below			Y060
Alpha 2 Macroglobulins, Qn	H	372	mg/dL	110 - 276	Y060
Haptoglobin	L	30	mg/dL	34 - 200	Y060
Apolipoprotein A-1	L	104	mg/dL	110 - 205	Y060
Bilirubin, Total		0.6	mg/dL		Y060
Newborns, term and near term:					
24 hours old:		0.0 - 8.0			
48 hours old:		0.0 - 13.2			
72 hours old:		0.0 - 15.6			
96 hours to 1 month old:		0.0 - 16.6			
Children 1 month and older and Adults:		0.0 - 1.2			
GGT	H	112	IU/L	0 - 60	Y060
ALT (SGPT)	H	354	IU/L	0 - 40	Y060

Interpretations:
Quantitative results of 6 biochemical tests are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) for liver fibrosis (METAVIR F0-F4) and for necroinflammatory activity (METAVIR A0-A3).
Fibrosis Scoring:
<0.21 = Stage F0 - No fibrosis
0.21 - 0.27 = Stage F0 - F1
0.27 - 0.31 = Stage F1 - Portal fibrosis
0.31 - 0.48 = Stage F1 - F2
0.48 - 0.58 = Stage F2 - Bridging fibrosis with few septa
0.58 - 0.72 = Stage F3 - Bridging fibrosis with many septa
0.72 - 0.74 = Stage F3 - F4
>0.74 = Stage F4 - Cirrhosis

Performing Site Legend on Last Page of Report

* Report times for Mayo performed tests are CST/CDT

TEST SITE

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,FHFIB N	SA00064516	47	F	SA00064516
Ordering Phys CLIENT,CLIENT				**DOB** 06/10/1966
Client Order # SA00064516	**Account Information**			**Report Notes**
Collected 11/18/2013 08:00	C7028846-DLMP Rochester SDSC 2 - Client Support Rochester, MN 55901			
Printed 11/20/2013 08:22				

Test	Flag	Results	Unit	Reference Value	Perform Site*

Necroinflamm Activity Scoring:
<0.17 = Grade A0 - No Activity
0.17 - 0.29 = Grade A0 - A1
0.29 - 0.36 = Grade A1 - Minimal activity
0.36 - 0.52 = Grade A1 - A2
0.52 - 0.60 = Grade A2 - Moderate activity
0.60 - 0.62 = Grade A2 - A3
>0.62 = Grade A3 - Severe activity

Limitations:
The negative predictive value of a Fibrotest score <0.31 (absence of clinically significant fibrosis) was 85% when compared to liver biopsy in 1,270 HCV infected patients with a 38% prevalence of significant liver fibrosis (F2, 3 or 4). The positive predictive value of a Fibrotest score >0.48 (F2, 3, 4) was 61% in that same patient cohort. HCV FibroSURE is not recommended in patients with Gilbert Disease, acute hemolysis (e.g. HCV ribavirin therapy mediated hemolysis), acute hepatitis of the liver, extra-hepatic cholestasis, transplant patients, and/or renal insufficiency patients. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis and necroinflammatory activity in the liver.

Comment:
The performance characteristics of this test have been determined by LabCorp. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not currently required. LabCorp is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and is certified to perform high complexity testing.

Results and Interpretation Provided by:
LabCorp RTP
1912 Alexander Drive
Research Triangle Park, NC 27709

* Performing Site:

Y060	LabCorp Burlington 1447 York Court Burlington, NC 27215-2230	Lab Director:

TEST SITE